Ariad Pharmaceuticals Inc fka ARIA

[DonShimoda]

How some people come up with all these being worth $7.8 billion (when Dendreon and Human Genome Sciences aren't even remotely worth that much) is beyond me.

I just searched this board and wasn't able to find one instance of a post containing the term "$65". It seems like you're just trying to give new life to old arguments you've had elsewhere. I for one would appreciate it if you left the baggage at the door.

As far as Ridaforolimus goes, we'll know soon enough but your view that it "isn't going to earn much of a revenue stream in sarcoma due to several other compounds in the clinic" seems mistaken given that ZIOP is actually complementary and not competitive. If successful, the combination of palifosfamide + doxorubicin should actually lead to a greater opportunity for ridaforolimus in the maintenance setting due to the longer PFS and improved patient stability.